Navigation Links
First results from hospital trials testing
Date:10/28/2008

NEW YORK, NY (October 28, 2008) The first stage of the U.S. Department of Defense-funded clinical trials exploring the role of hospital touch surfaces in the transmission of infectious pathogens has been completed and the researchers reported their findings in a poster session at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. on Tuesday, October 28. The data presented describe the first results of a three phase study where the bioload found on stainless steel, plastic and aluminum objects in intensive care unit rooms were measured. Phases two and three of the study are ongoing. During these phases, the bioload on identical objects made of microbiocidal copper will be measured to determine the effectiveness of copper at combating hospital-acquired infections.

The findings being presented at ICAAC show that the most heavily contaminated objects are those in closest proximity to the patients: bed rails, call buttons and chairs were found to have the highest levels of staphylococcus, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). These pathogens can survive for extended periods of time on such objects, which act as reservoirs for the bacteria.

Independent laboratory studies have shown that copper, brass and bronze are more than 99.9 percent effective in killing potentially deadly pathogens, such as MRSA, which are commonly found in healthcare facilities. In response to these findings, the Environmental Protection Agency has registered copper, brass and bronze as antimicrobial materials, allowing public health claims to be made about them.

A similar clinical trial is also being conducted at Selly Oak Hospital, University Hospital Birmingham in the U.K. Results from this trial, also being presented at ICAAC, show a 90-95 percent reduction in contamination on copper alloy surfaces compared to the controls.


'/>"/>

Contact: Geralyn Lederman
glederman@kellencompany.com
212-297-2118
Copper Development Association
Source:Eurekalert

Page: 1

Related biology news :

1. Which came first, the moth or the cactus?
2. First all-African GM crop is resistant to maize streak virus
3. Scientists retrace evolution with first atomic structure of an ancient protein
4. CU-Boulder team discovers first ancient manioc fields in Americas
5. First finding of a metabolite in 1 sex only
6. First orchid fossil puts showy blooms at some 80 million years old
7. First individual genome sequence published
8. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
9. UNH becomes first university in nation to use landfill gas as primary energy source
10. Scientists in first global study of poison gas in the atmosphere
11. Weight gain between first and second pregnancies associated with increased odds of male second child
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology: